EUCTR2004-002547-27-GB进行中（未招募）1 期
Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease - CIRTED
niversity of Bristol0 个研究点目标入组 160 人开始时间: 2005年8月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinical Activity Score > or = 4; Worst Eye OR OR ??? 2 (worst eye) with a history of proptosis or motility restriction of less than 6 months duration2.Past or present history of abnormal Thyroid Gland Function OR a clinical diagnosis of TED made and confirmed by ??? 2 muscle involvement on CT or MRI scan
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •1. Age <20 or >75 yrs2. Use of radioiodine within the last 3 months3. Preexisting diabetes mellitus (not simply steroid induced disease from recent therapy)4. Contraindication to either prednisolone or azathioprine5.Thiopurine Methyltransferase (TPMT) inactivity6.Clinical Activity Score > 4 without proptosis or motility restriction(Patients who do not improve with steroid treatment in the first month after enrolment will leave the trial and not be randomised)
研究者
相似试验
已完成
不适用
Combined Immunosuppression and Radiotherapy in Thyroid Eye DiseaseISRCTN22471573niversity of Bristol (UK)100
已完成
不适用
Combined Local Immunotherapy and Radiotherapy in metastatic MelanomaMetastatic melanomaMalignant melanoma of skinCancerISRCTN26232057St George's Healthcare NHS Trust (UK)30
进行中（未招募）
1 期
_ocalised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapyEUCTR2018-000708-40-FRICANCER120
招募中
2 期
eoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary EfficacyOesophageal cancergastro-oesophageal junction cancerCancer - Oesophageal (gullet)ACTRN12619000288123Southern Adelaide Local Health Network Inc52
进行中（未招募）
1 期
Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effectson small-cell lung cancer (NSCLC) Stage: T1-3( =5cm)N0M0)EUCTR2016-005187-34-GBThe Royal Marsden NHS Foundation Trust31